TFE3-Rearranged Renal Cell Carcinoma — Trials

TFE3-Rearranged Renal Cell Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

4 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 2
Recruiting: 0
Ph III recruiting: 0
Growth YoY: —
Industry share: 0%
Top sponsor: M.D. Anderson Cancer Center
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (0)

clinicaltrialsPublishedShowing 1–1 of 1 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT03685448	ANZUP - Non-clear Cell Post Immunotherapy CABozantinib (UNICAB)(UNICAB)	completed	Phase 2	35	Australian and New Zealand Urogenital and Prostate Cancer Trials GroupOTHER	1	Aug 8, 2025	clinicaltrials

Data updated 22 days agoSource updated Aug 8, 2025source: clinicaltrials